https://doi.org/10.55788/5d2844c4
The combination of ibrutinib and venetoclax, an oral, once-daily, chemotherapy-free regimen, has recently been approved in the EU as treatment for patients with previously untreated CLL. At ASH 2022, Prof. John Allan (Weill Cornell Medicine, NY, USA) presented long-term follow-up data of the phase 2 CAPTIVATE study (NCT02910583), a trial that evaluated the efficacy and safety of this combination, for which the primary results were presented previously [1,2]. After completion of the pre-randomised combination therapy, patients were randomised 1:1 to continued ibrutinib or placebo. The current analysis focused on the comparison between these arms in a cohort of patients that displayed confirmed undetectable minimal residual disease (uMRD; n=86) after completion of the pre-randomised combination treatment.
Prof. Allan showed that the 3-year disease-free survival rates were high and not significantly different in the 2 arms of the study, with a rate of 85% in the placebo arm and a rate of 93% in the ibrutinib arm (HR 0.44; 95% CI 0.13–1.45; log-rank P=0.16). Furthermore, 36 months after randomisation, MRD negativity was observed in 63% of the participants on ibrutinib and in 58% of those on placebo. The 4-year progression-free survival rates were 95% and 88% in the ibrutinib arm and placebo arm, respectively. Finally, Prof. Allan mentioned that the incidence of adverse events post-randomisation was low and that no new grade ≥3 haemorrhagic events were reported.
In conclusion, the combination regimen of ibrutinib and venetoclax resulted in deep and durable response in newly diagnosed patients with CLL.
- Allan JN, et al. Treatment outcomes after undetectable MRD with first-line ibrutinib plus venetoclax: fixed-duration treatment (placebo) versus continued ibrutinib with up to 5 years follow-up in the CAPTIVATE study. Abstract 92, ASH 64th Annual Meeting, 10–13 December 2022, New Orleans, LA, USA.
- Wierda WG, et al. J Clin Oncol. 2021;39(34):3853–3865.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Excellent results for triplet regimen in FLT3-mutated AML Next Article
Zanubrutinib wins battle of BTK inhibitors in relapsed or refractory CLL/SLL »
« Excellent results for triplet regimen in FLT3-mutated AML Next Article
Zanubrutinib wins battle of BTK inhibitors in relapsed or refractory CLL/SLL »
Table of Contents: ASH 2022
Featured articles
Acute Lymphoblastic Leukaemia
Blinatumomab candidate for standard-of-care in newly diagnosed B-ALL
High-dose methotrexate or standard interim maintenance in young patients with ALL?
Acute Myeloid Leukaemia
Excellent results for triplet regimen in FLT3-mutated AML
MRD by qPCR prognostic of outcomes in venetoclax-treated NPM1-mutated AML
Promising results for triplet therapy with magrolimab in AML
Should we use intensive chemotherapy prior to allo-HCT in relapsed/refractory AML?
Chronic Leukaemia
Zanubrutinib wins battle of BTK inhibitors in relapsed or refractory CLL/SLL
Ibrutinib plus venetoclax displays long-term benefits in CLL
Multiple Myeloma
Talquetamab further investigated in heavily pre-treated MM after promising phase 2 data
Promising results of elranatamab for MM in phase 2 MagnetisMM-3 trial
Deep and durable responses for quadruple therapy in smouldering MM
Ultra-sensitive MRD assessment in MM with BloodFlow
CAR-Hematotox score proves useful in relapsed/refractory MM
Head-to-head: VMP versus Rd in transplant-ineligible MM
Lymphoma
Ibrutinib added to ASCT improves clinical outcomes in mantle cell lymphoma
High-dose chemotherapy plus ASCT superior to standard immuno-chemotherapy in primary CNS lymphoma
Odronextamab has considerable anti-tumour effects in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma
Excellent results for AFM13-complexed NK cells in CD30-positive lymphoma
CAR-Hematotox score predicts toxicity, infections, and clinical outcomes in MCL
Myeloproliferative Neoplasms
Efgartigimod successful in immune thrombocytopenia
INCA033989: novel investigational agent for CALR-mutated MPN
Ruxolitinib mediates clonal evolution of RAS pathway mutations in MPN
Immune Thrombocytopenia
Long-term risk for haematologic disease in persistent, isolated mild thrombocytopenia
Various Topics
C1 inhibitor deficiency linked to thrombosis
Durable responses to gene therapy in haemophilia A
Long-term benefits from beti-cel in transfusion-dependent β-thalassaemia
Neutrodiet: non-restricted diet is the preferred option after SCT
Iptacopan offers solution for patients with PNH and residual anaemia after standard-of-care
Novel therapy may replace standard-of-care prophylaxis for GVHD
LMWH does not result in higher live birth rates in women with inherited thrombophilia
Related Articles
February 20, 2023
C1 inhibitor deficiency linked to thrombosis
February 20, 2023
Long-term benefits from beti-cel in transfusion-dependent β-thalassaemia
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy